Qusacpharma.com

The most recent version of this document is available on our website at www.qusacpharma.com under products section Personal Protective Equipment
Section 1.0 Product Identification and Company Information Common Name
or Trade Name
Number(s)
Manufacturer
Common Name
Synonyms
Chemical Formula
Emergency 24hrs
Information Business hours
Section 2.0 Composition and Information on Ingredients % by Weight
Emergency Overview
WARNING! HARMFUL IS SWALLOWED OR INHALED. CAUSES IRRITATION TO SKIN, EYES AND RESPIRATORY TRACT. POSSIBLE BIRTH DEFECT HAZARD. MAY CASE DEFECTS BASED ON ANIMAL DATA. Potential Health Effects
The most recent version of this document is available on our website at www.qusacpharma.com under products section Inhalation of dust may irritate the mucous membranes and respiratory tract. High Inhalation
concentrations may produce effects paralleling ingestion. Toxic. The adult mean lethal dose is approximately 10 g. Large doses may produce Ingestion
palpitation, excitement, insomnia, dizziness, headache and vomiting Skin Contact
Causes irritation to skin, Symptoms include redness, itching and pain Eye Contact
Excessive use of caffeine may lead to digestive disturbances, constipation, Chronic Exposure
palpitations, shortness of breath and depressed mental states. Possible teratogen. May cause congenital malformation in the fetus Remove to fresh air, If not breathing, give artificial respiration. If breathing is Inhalation
difficult, give oxygen. Get medical attention Induce vomiting immediately as directed by medical personnel. Never give anything Ingestion
by mouth to an unconscious person. Get medical attention Immediately flush skin with plenty of water for at least 15 minutes. Remove Skin Contact
contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. Immediately flush eyes with plenty of water for at least 15 minutes, lifting lower and Eye Contact
upper eyelids occasionally. Get medical attention immediately As with most organic solids, fire is possible at elevated temperatures or by contact Fine dust dispersed in air in sufficient concentrations, an in the presence of an Explosion
ignition source is a potential dust explosion hazard. Fire Extinguishing Media
Water spray, dry chemical, alcohol foam, or carbon dioxide In the event of a fire, wear full protective clothing and NIOSH-approved self- Special Information
contained breathing apparatus with full face piece operated in the pressure demand or other positive pressure mode. Remove all sources of ignition. Ventilate area of spill. Wear appropriate personal protective equipment as specified in Section 8. Clean up spills in a manner that does not disperse dust into the air. Use non-sparking tools and equipment. Reduce airborne dust and prevent scattering by moistening with water. Pick up spill for recovery or disposal. Keep in tightly closed container, stored in a cool, dry, ventilated area. Protect against physical damage. Fiber drum containers must be kept dry and away from excessive moisture. Empty containers of this material may be hazardous when empty since they retain product residues (Dust, Solids); observe all warnings and precautions listed for the product. Section 8.0 Exposure Controls/Personal Protection Airborne Exposure Limits
The most recent version of this document is available on our website at www.qusacpharma.com under products section A system of local and/or general exhaust is recommended to keep employee exposures as low as possible. Local exhaust ventilation is generally preferred Ventilation System
because it can control the emissions of the contaminant at its source, preventing dispersion of it into the general work area. NIOSH Approved, for conditions of use where exposure to the dust or mist is apparent, a half-face dust/mist respirator may be worn. For emergencies or Personal Respirators
instances where the exposure levels are not known, use a full-face positive-pressure, air-supplied respirator. Wear impervious protective clothing, including boots, gloves, lab coat, apron or Skin Protection
coveralls, as appropriate, to prevent skin contact. Use chemical safety goggles and/or full face shield where dusting or splashing is Eye Protection
Section 9.0 Physical and Chemical Properties Appearance
Molecular Weight
pH (1% soln/water)
Solubility
Melting Point
Boiling Point
Specific Gravity
Section 10.0 Stability and Reactivity Data Stability
The product is stable under normal conditions of use. Conditions of Instability
Hazardous Decomposition
Burning may produce carbon monoxide, carbon dioxide, nitrogen oxides Hazardous Polymerization
Incompatible with strong oxidizers, iodine silver salts, tannins, and strong solutions Incompatibilities
Carcinogenic effects: 3 (Not classifiable for human.) by IARC. Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. May cause damage to the following organs: heart, gastrointestinal tract, central nervous system (CNS). Chronic Effects on Humans
May cause cancer (tumorigen) based on animal studies. May cause reproductive and fetal effects. May cause digestive tract disturbances (increased gastric acid, and pepsin secretion and a decrease in lower esophageal sphincter pressure), cardiovascular disturbances. Since it is a CNS stimulant, it may also affect the Central Nervous System (CNS). Special Remarks on Toxicity LD50 - Route: Oral; Dose: 192 mg/kg
The most recent version of this document is available on our website at www.qusacpharma.com under products section May cause gastrointestinal (digestive) tract irritation with epigastric pain, abdominal cramps, nausea, vomiting and diarrhea. Affects metabolism and cardiovascular system including increase in metabolism, flushing, palpitations, rapid heart rate, Special Remarks on other
dysrhythmias, ypotension, blood pressure elevation and weight loss, metabolic Toxic Effects on Humans
acidosis. May affect brain and behavior/central nervous system. Symptoms may and Acute Potential Health
include nervousness, anxiety, restlessness, insomnia, dizziness, tremor, seizures, convulsions, hallucinations, somnolence, toxic psychosis, tremors, convulsions, ataxia. May also affect blood, respiration (hyperventilation) and urinary system (mild increase in urinary volume and urinary sodium excretion), and may directly produce hypokalemia. Possibly hazardous short term degradation products are not likely. However, long Products of Biodegradation
Toxicity of the Products of
Products of degradation are less toxic than the product itself. Biodegradation
Waste must be disposed of in accordance with federal, state and local environmental Control regulations. TDG Act Canada
Classification
DOT Classificatio
Identification
(Shipping name)
Identification
(Technical name)
TDG Special Provisions
Special Provision 16 regarding the use of Technical name and Shipping names. for Transport
TDG and DOT (Pictogram)
ADR (Europe)
(Pictograms)

Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). Other Regulations
EINECS: This product is on the European Inventory of Existing Commercial Chemical WHMIS (Canada)
Not controlled under WHMIS (Canada). Does not have a WHMIS classification R22- Harmful if swallowed. R40- Possible risks of irreversible effects. DSCL (EEC)
R63- Possible risk of harm to the fetus. S2- Keep out of the reach of children. The most recent version of this document is available on our website at www.qusacpharma.com under products section HMIS (U.S.A.)
DSCL (Europe)
(Pictograms)

Validated by Q.C.
Verified by Q.A.
Date last revision
Exspires
All chemicals may pose unknown hazards and should be used with caution. This Material Safety Data Sheet (MSDS)
applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomes
contaminated, it may pose hazards not mentioned in this MSDS.
It shall be the user's responsibility to develop proper methods of handling and personal protection based on the actual
conditions of use. While this MSDS is based on technical data judged to be reliable, QUSAC Pharma Inc. assumes no
responsibility for the completeness or accuracy of the information contained herein.

Source: http://www.qusacpharma.com/images/pdf/natural_caffeine_msds.pdf

Microsoft word - e-concurrences june 2008.doc

Romanian Competition Council Decision 15/12.03.2008 on market-sharing cartel and Public Health Ministry infringement on the insulin market Georgeta Harapcea, Senior Associate Following an investigation initiated in July 2005 and which has lasted for almost 3 years, the Romanian Competition Council (RCC) has fined one pharmaceutical producer and three distributors for participation

Aviva actions croissance 2011-03-31.xls

Forme juridique Objectif de gestion Le FCP a pour objectif d’obtenir une performance supérieure à celle de l’indicateur de référence pour optimiser le rendement de contratsd'assurance-vie libellés en unités de compte relevant de l'option dite "DSK". Date de création Catégorie Engine - EuroPerformance Performances * Cumulées Classification AMF

Copyright © 2010-2014 Online pdf catalog